Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

Related Articles by Review for PubMed (Select 18470643)

1.

PEGylated adenovirus for targeted gene therapy.

O'Riordan CR, Song A.

Methods Mol Biol. 2008;434:133-60. doi: 10.1007/978-1-60327-248-3_9.

PMID:
18470643
2.

[Development of pegylated adenovirus vector for cancer gene therapy].

Eto Y, Yoshioka Y, Asavatanabodee R, Mizuguchi H, Mukai Y, Okada N, Nakagawa S.

Yakugaku Zasshi. 2008 Dec;128(12):1733-42. Review. Japanese.

3.

Development of PEGylated adenovirus vector with targeting ligand.

Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S.

Int J Pharm. 2008 Apr 16;354(1-2):3-8. Epub 2007 Aug 24. Review.

PMID:
17904316
4.

Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.

Kreppel F, Kochanek S.

Mol Ther. 2008 Jan;16(1):16-29. Epub 2007 Oct 2. Review.

PMID:
17912234
5.

Adenovirus vectors for gene delivery.

Benihoud K, Yeh P, Perricaudet M.

Curr Opin Biotechnol. 1999 Oct;10(5):440-7. Review.

PMID:
10508634
6.

From gene therapy to virotherapy for ovarian cancer.

Stoff-Khalili MA, Dall P, Curiel DT.

Minerva Ginecol. 2004 Dec;56(6):503-14. Review.

PMID:
15729203
7.

Genetic targeting strategies for adenovirus.

Noureddini SC, Curiel DT.

Mol Pharm. 2005 Sep-Oct;2(5):341-7. Review.

PMID:
16196486
8.

FGF2-targeted adenoviral vectors for systemic and local disease.

Sosnowski BA, Gu DL, D'Andrea M, Doukas J, Pierce GF.

Curr Opin Mol Ther. 1999 Oct;1(5):573-9. Review.

PMID:
11249664
9.

Novel vectors for in vivo gene delivery to vascular tissue.

White K, Nicklin SA, Baker AH.

Expert Opin Biol Ther. 2007 Jun;7(6):809-21. Review.

PMID:
17555367
10.

Vector retargeting for cancer gene therapy.

Wei W, Xue JL, Tian L.

Ai Zheng. 2009 Jan;28(1):86-90. Epub 2009 Jan 22. Review.

PMID:
19448427
11.

Biology of adenovirus and its use as a vector for gene therapy.

McConnell MJ, Imperiale MJ.

Hum Gene Ther. 2004 Nov;15(11):1022-33. Review. No abstract available.

PMID:
15610603
12.

Gene therapy for ovarian cancer: progress and potential.

Kirby TO, Curiel DT, Alvarez RD.

Hematol Oncol Clin North Am. 2003 Aug;17(4):1021-50. Review.

PMID:
12959190
13.

Targeting vectors for cancer gene therapy.

Nakamura K, Kato K, Tanaka T, Hamada H.

Front Biosci (Elite Ed). 2009 Jun 1;1:332-40. Review.

PMID:
19482650
14.

The current status of adenovirus-based cancer gene therapy.

Shirakawa T.

Mol Cells. 2008 Jun 30;25(4):462-6. Epub 2008 May 6. Review.

15.

Adenovirus receptors: implications for tropism, treatment and targeting.

Arnberg N.

Rev Med Virol. 2009 May;19(3):165-78. doi: 10.1002/rmv.612. Review.

PMID:
19367611
16.

Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications.

Parker AL, Nicklin SA, Baker AH.

Curr Opin Mol Ther. 2008 Oct;10(5):439-48. Review.

PMID:
18830919
17.

Engineering targeted viral vectors for gene therapy.

Waehler R, Russell SJ, Curiel DT.

Nat Rev Genet. 2007 Aug;8(8):573-87. Epub 2007 Jul 3. Review.

PMID:
17607305
18.
19.

Cancer gene therapy with targeted adenoviruses.

Bachtarzi H, Stevenson M, Fisher K.

Expert Opin Drug Deliv. 2008 Nov;5(11):1231-40. doi: 10.1517/17425240802507636 . Review.

PMID:
18976133
20.

Gene therapy: some results, many problems to solve.

Fischer A.

Cell Mol Biol (Noisy-le-grand). 2001 Dec;47(8):1269-75. Review.

PMID:
11838947
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk